Health Minister Tony Clement says he's launching an immediate review of why Canada has failed to deliver on a pledge to get low-cost AIDS drugs to countries in need. He has his work cut out. There are critical hurdles to be overcome, according to industry officials and experts interviewed by the Star. They include: a lack of financial incentives for generic drug companies; the cumbersome process for acquiring licences to produce the drugs and, most problematic, deep-rooted hostilities between generic and brand-name drug companies. "Exhibit A is not a single pill has flowed through the system and got to the people who need it," Clement said yesterday during a session on vaccines at the International AIDS Conference in Toronto. "We need legislation that works." Everything is on the table, according to Clement, including forcing brand-name companies to relinquish their patents through issuing compulsory licences."It's all money," said Ariel Katz, a University of Toronto professor who studies intellectual property and competition law.